22ndURA International Seminar

Okayama University

Date: Thursday - (木) 19th September 2024 --- Time: 16:30
VENUE: Tsushima Campus – International House

Dominique BAGNARD(HYBRID mode, broadcasted on ZOOM)The talk will briefly introduce organoids, with focus on what they are and how they can befabricated. The seminar will delve into the applications of organoids in drug testing anddisease modeling, highlighting the advantages of using organoids over traditional cell
cultures and animal models. Moreover, the talk attendees will be taken on board an actual
journey into the complexity of these organ-like structures, focusing on the case ofcerebroids. From the identification of biomarkers to the use of electron microscopy, theintricate process of developing cerebroids will be discussed in detail.
The seminar will also provide an overview of organoid-on-a-chip technology and its
integration in drug discovery, presenting case studies that showcase successful drug
development using these technologies.
Future directions and potential challenges in the field will also be discussed, offering acomprehensive understanding of the subject.

NB: The talk is for all audiences including students.
Organized byGraduate School of Medicine,Dentistry and PharmaceuticalSciences
Organization for Research andInnovation Strategy

Participation is free of charge but Advanced
Registration is Mandatory. Deadline: September14th
a - https://forms.gle/adTpH3iagVCyEq9B6
b - CC to bernard-chenevier@cc.okayama-u.ac.jp
ZOOM link will be sent to participants registeredoutside Okayama.

https://www.orsd.okayama-u.ac.jp/ura_eng/

SPEAKER Short Bio
Professor Dominique Bagnard – Strasbourg University - has been
directing an INSERM group research since 2003. As an expert
in neurobiology, brain diseases, and neuro-oncology.
As the Director of Research and Medalis Director at theStrasbourg Institute for Drug Design and Drug Development(IMS ps://ims.unistra.fr/) ), Pr. Bagnard leads cutting-edge research initiatives in drug discoveryand development.
Pr Bagnard also serves as the Dean of the “École Supérieure de Biotechnologie de Strasbourg”(ESBS) (https://esbs.unistra.fr/), where he oversees the education and training of future leaders
in biotechnology. ESBS is positioned as a premier institution in the field.
From the early stages of his career, Pr. Bagnard has been actively involved in scientificpublishing. He is the founder and Editor-in-Chief until 2023 of the international journal Cell
Adhesion and Migration* which disseminates critical research findings to the global scientificcommunity.
His entrepreneurial spirit is clearly reflected in the field of technology transfer: he founded two
startup companies, Peptimimesis Pharma and Adaptherapy. These ventures companies aim tobring innovative therapies to the marketdemonstrating his commitment to bridging the gap
between scientific discovery and clinical applications.
* https://www.tandfonline.com/kcam20
Dominique Bagnard's multifaceted career,
spanning academia, research, and entrepreneu
rship, highlights his strong commitment in advancing global understanding of neurobiology anddeveloping new therapeutic strategies for brain
diseases. His work continues to impact the fieldsof neuro-oncology and biotechnology, fostering
innovation and collaboration across disciplines.

【Inquiry】
Bernard CHENEVIER
Senior URA, Okayama University
bernard-chenevier＠cc.okayama-u.ac.jp
Ken TAKAHASHI
Professor – Graduate School of Medicine,
Dentistry andPharmaceutical Sciences, – Okayama
Universitytakah-k2@okayama-u.ac.jp